Precision Medicine Developer Using Patient-Derived 3D Micro-Tissues
InvivoSciences, Inc. (IVS) is a precision medicine company personalizing the drug development process by introducing the next-generation, best-in-class patient-derived and gene-edited human samples, including automated, scalable, functional 3D engineered micro-human heart tissue platform. Our unique integration of cell & tissue handling automation, tissue phenotyping assays, computational biology (AI), and human organ/tissue data enables rapid identification of safety and efficacy profile of a given treatment for specific patient group significantly cost-effective prior to expensive clinical trials. IVS’s technology for matchmaking the best treatment for the patient group will expedite the early discovery and clinical trials as well as support post-product launch monitoring. Thus, our approach brings tremendous value to pharmaceutical developers who are evaluating the safety and efficacy of new drug candidates before investing significant resources in human trials and who wants to increase their success rate of drug approvals. As such the technology can dramatically help 1) mitigate the historically high risk of clinical trial failure because of the treatment-induced arrhythmia, and heart failure and 2) develop patient-specific heart failure treatments.
John’s Micro Hearts Find The Best Treatment for John
Our founders’ personal experience drove us to start doing what we do now. Thanks to the US National Institute of Health and generous contributors. Their long-term and extensive support enabled IVS to develop and validate human induced pluripotent stem cell (iPSC) derived micro-heart tissue called NuHeart™. IVS’s core competencies include an automated process of mass-producing micro NuHearts™ derived from various lines of patient-specific and gene-edited iPSCs and their high-throughput phenotypic assay platform.
Illustration courtesy of TEDx Talk
Why we do what we do?
InvivoSciences, Inc. (IVS’s) vision is to transform Biopharmaceutical companies to safe and effective precision medicine providers for patients in a wide range of therapeutic areas including cardiac, cancer, and rare diseases. IVS provides patented, automated human organ-on-a-chip predictive assay technology platforms for drug development. We can also perform reliable toxicity screening rapidly, accurately, and cost effectively.
InvivoSciences, Inc. develops personalized Micro-Organs for improving Human Health. IVS offers phenotypic analysis using its personalized organotypic human samples for accurate prediction of patient-specific safety and efficacy of drug candidates for the pre-clinical development of personal biopharmaceutical products and their safety analysis. InvivoSciences, Inc. is an innovative drug discovery company with pre-clinical program partnerships in heritable cardiomyopathies and cardio-oncology.
IVS’s core competencies include an automated process of mass-producing micro NuHearts derived from various lines of patient-specific and gene-edited iPSCs and their high-throughput phenotypic assay platform.